Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III Sells 55,453 Shares

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 55,453 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $8.28, for a total transaction of $459,150.84. Following the completion of the transaction, the director now directly owns 1,011,974 shares of the company’s stock, valued at $8,379,144.72. This represents a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pulmonx Stock Performance

LUNG traded down $0.04 on Monday, reaching $8.92. The company had a trading volume of 597,603 shares, compared to its average volume of 342,603. The stock has a market cap of $352.25 million, a P/E ratio of -6.19 and a beta of 0.64. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $11.10. The company’s fifty day moving average is $6.53 and its 200 day moving average is $6.79.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. As a group, analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LUNG shares. Stifel Nicolaus dropped their target price on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Wells Fargo & Company dropped their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Finally, Citigroup reiterated a “neutral” rating and set a $7.50 target price (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.75.

Hedge Funds Weigh In On Pulmonx

A number of hedge funds have recently bought and sold shares of the business. 272 Capital LP acquired a new position in shares of Pulmonx during the 3rd quarter worth approximately $25,000. BNP Paribas Financial Markets acquired a new stake in Pulmonx during the fourth quarter worth approximately $43,000. R Squared Ltd bought a new position in Pulmonx during the 4th quarter worth $46,000. ProShare Advisors LLC acquired a new position in Pulmonx in the 4th quarter valued at $72,000. Finally, Stifel Financial Corp bought a new stake in shares of Pulmonx during the 4th quarter valued at $81,000. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.